Frontier Biotechnologies Inc. (SHA:688221)
China · Delayed Price · Currency is CNY 18.98
-0.48 (-2.47%)
At close: Jul 29, 2026
Frontier Biotechnologies Company Description
Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients’ health in China.
It offers Aikening, an IV fusion inhibitor for dual therapy of HIV-1. The company’s pipeline products include FB2004 indicated for HBV; FB7011 and FB7013 for IgA nephropathy; FB7012 to treat hyperuricemia and gout; FB7041 to treat tumors; FB7024 for the treatment of hyperlipidemia; FB7023 to treat ASCVD; FB7033 for the treatment of MASH; FB4001 for osteoporosis; and FB3002 for pain management.
Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.
Frontier Biotechnologies Inc.
| Country | China |
| Founded | 2002 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 314 |
| CEO | Dong Xie |
Contact Details
Address: Building E-2, Greenland Window Nanjing, 211199 China | |
| Phone | 86 25 6964 8375 |
| Website | frontierbiotech.com |
Stock Details
| Ticker Symbol | 688221 |
| Exchange | Shanghai Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100005XF5 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Dong Xie Ph.D. | Founder, Chairman, President and Chief Scientific Officer |
| Qi Shao | Senior Vice President, Chief Operating Officer and Chief Financial Officer |
| Dr. Rongjian Lu Ph.D. | Chief Technology Officer and Director |
| Hangzhou Lv | Senior Vice President of Marketing and Sales |
| Dr. Changjin Wang Ph.D. | MD, CBO and Director |
| Qianya Gao | Vice President, Deputy GM and Secretary of the Board of Directors |
| Xin Guan | Accounting Supervisor |
| Michael Hu | C.M.O. |
| Michael Wang | Senior Vice President and Head of Infectious Diseases Therapy Area |